| 51 |
26295926 | Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability. | 2015 Dec |
2 |
| 52 |
24008922 | Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease. | 2014 |
1 |
| 53 |
24148813 | Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. | 2014 Feb |
1 |
| 54 |
24271646 | Effect of moderate liver impairment on the pharmacokinetics of opicapone. | 2014 Mar |
1 |
| 55 |
24716406 | Inhibition of catechol-o-methyltransferase (COMT) by myricetin, dihydromyricetin, and myricitrin. | 2014 Mar |
5 |
| 56 |
24770794 | Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition. | 2014 Nov |
8 |
| 57 |
24830331 | Entacapone reduces cortical activation in Parkinson's disease with wearing-off: a f-MRI study. | 2014 |
2 |
| 58 |
24925090 | Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. | 2014 Sep |
3 |
| 59 |
25154960 | Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study. | 2014 Oct |
2 |
| 60 |
23206800 | Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration. | 2013 Feb 25 |
3 |
| 61 |
23237479 | Effects of transcranial direct current stimulation (tDCS) on executive functions: influence of COMT Val/Met polymorphism. | 2013 Jul-Aug |
1 |
| 62 |
23948989 | Levodopa in the treatment of Parkinson's disease: current status and new developments. | 2013 Jan 1 |
1 |
| 63 |
23994933 | [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study]. | 2013 |
1 |
| 64 |
24234932 | Association Between Catechol-O-Methyltransferase (COMT) Gene Polymorphisms, Parkinson's Disease, and Levodopa Efficacy. | 2013 Nov 15 |
3 |
| 65 |
24532988 | Pharmacogenetics of Parkinson's disease - through mechanisms of drug actions. | 2013 Dec |
1 |
| 66 |
22123108 | Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review. | 2012 Jan 13 |
2 |
| 67 |
22136069 | Intestinal levodopa infusion and COMT inhibition - a promising link. | 2012 Jun |
1 |
| 68 |
22136163 | Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. | 2012 Jun |
3 |
| 69 |
22483291 | Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment. | 2012 May |
4 |
| 70 |
22863920 | Effects of 3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on locomotor activity and dopamine turnover in rats. | 2012 |
4 |
| 71 |
23020119 | Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells. | 2012 Nov |
4 |
| 72 |
23093014 | The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease. | 2012 |
2 |
| 73 |
21164341 | Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients. | 2011 Jan-Feb |
2 |
| 74 |
21280081 | The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. | 2011 Jan |
5 |
| 75 |
21533995 | Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. | 2011 Jun |
4 |
| 76 |
21538606 | Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors. | 2011 May 27 |
3 |
| 77 |
21738693 | Comparison of endothelial progenitor cells in Parkinson's disease patients treated with levodopa and levodopa/COMT inhibitor. | 2011 |
1 |
| 78 |
22053701 | Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease. | 2011 Sep |
2 |
| 79 |
22093536 | Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. | 2011 Dec |
1 |
| 80 |
25205926 | Cell based therapies in Parkinson's Disease. | 2011 Apr |
1 |
| 81 |
19676096 | Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. | 2010 Mar 5 |
1 |
| 82 |
19879254 | Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus. | 2010 Jan 14 |
1 |
| 83 |
19909787 | Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. | 2010 Jan 14 |
2 |
| 84 |
20077469 | The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF. | 2010 Feb 15 |
1 |
| 85 |
20464572 | Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients. | 2010 Oct |
2 |
| 86 |
20582993 | Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. | 2010 Jul |
1 |
| 87 |
20700524 | Dual beneficial effects of (-)-epigallocatechin-3-gallate on levodopa methylation and hippocampal neurodegeneration: in vitro and in vivo studies. | 2010 Aug 5 |
2 |
| 88 |
20812452 | [The effect of Stalevo-dosing on quality of life of Parkinsonian patients with wearing-off]. | 2010 Jul 30 |
1 |
| 89 |
20856911 | Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). | 2010 Sep 7 |
2 |
| 90 |
21095456 | Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition. | 2010 |
11 |
| 91 |
21095459 | Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms. | 2010 |
1 |
| 92 |
21095461 | The chemistry of catechol-O-methyltransferase inhibitors. | 2010 |
2 |
| 93 |
21095462 | Toxicology and safety of COMT inhibitors. | 2010 |
2 |
| 94 |
21095464 | Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. | 2010 |
1 |
| 95 |
19056347 | Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor. | 2009 Jan 16 |
2 |
| 96 |
19131039 | L-dopa therapy for Parkinson's disease: past, present, and future. | 2009 Jan |
2 |
| 97 |
19167259 | Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. | 2009 Aug |
1 |
| 98 |
19407449 | Levodopa: past, present, and future. | 2009 |
2 |
| 99 |
19538218 | Levodopa in the treatment of Parkinson's disease. | 2009 Sep |
1 |
| 100 |
19589043 | Levodopa/carbidopa/entacapone in Parkinson's disease. | 2009 Jul |
4 |